Why Nuvation Bio Stock Falling In Pre-market?

June 27, 2022 — 07:34 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Nuvation Bio Inc. (NUVB) announced the FDA has placed a partial clinical hold on the company's phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the company proactively paused enrollment of new patients.

David Hung, CEO of Nuvation Bio, said: "Based upon the recent development of uveitis as a potential safety signal, we will conduct an overall risk/benefit analysis of the NUV-422 program. With $737.7 million in cash as of March 31, 2022, we are well positioned to continue developing all of our internal product candidates."

Shares of Nuvation Bio were down 26% in pre-market trade on Monday.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Why Nuvation Bio Stock Falling In Pre-market?

Tags

Latest Articles